

Special Issue

Targeted Therapies for B-Cell Leukemia and Lymphoma

Message from the Guest Editors

Recent years have brought unprecedented progress in the treatment of leukemia and lymphoma. The chemotherapy that used to be the mainstay of anticancer therapy is being increasingly replaced by novel targeted therapies in both lymphoid and myeloid malignancies. Currently, two main strategies are in use, viz., immunotherapy and targeted small agent therapy, with more being approved and even more in clinical and preclinical development. Each tool appears to have its use, with immunotherapy being the most effective treatment for B-cell lymphoma and targeted small agents for indolent B-cell malignancies. In recent years, the treatment of B-cell lymphoid malignancies has been greatly improved by the development of targeted drugs, particularly Bruton's tyrosine kinase (BTK) inhibitors, phosphoinositide 3-kinases (PI3K) inhibitors and the BCL-2 inhibitor venetoclax. This Special Issue will include both original and review articles on approved targeted therapies, as well as emerging therapies for B-cell leukemia and lymphoma that are currently in preclinical and clinical development.

Guest Editors

Prof. Dr. Tadeusz Robak

Department of Hematology, Medical University of Lodz, Lodz, Poland

Prof. Dr. Iwona Hus

National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland

Deadline for manuscript submissions

closed (1 April 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/188177

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)